+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diagnostics UK Market Report 1st edition

  • Report
  • 261 Pages
  • May 2020
  • Region: United Kingdom
  • LaingBuisson
  • ID: 5027057

“Diagnostics are fundamental to the clinician’s understanding of their patient’s condition and the best treatment for them. The years between 2012 and 2018 have seen an 8-9% growth in the number of MRI and CT scans undertaken, while the number of pathology tests is growing at a rate of just over 2% per year. Given the insight that can be gained from testing and the benefits that it offers clinicians and patients alike, there is no reason to believe that when we emerge from the current crisis that this growth will not continue. While we predict continued downward pressure in pricing, demographic changes and pressure to catch up with testing rates in other counties point to sustained volume growth together with growth in the value of the market, albeit at a slower pace.

“While the trend has been away from outsourcing diagnostics from the NHS in recent years, the pressure to grow may well create further opportunities. Private imaging companies currently account for around 15% of the addressable market and diagnostics companies remain attractive to investors, reassured by the fact that payments are largely underwritten by public money. As we return to normal after Coronavirus, there is no reason to think that the UK diagnostics market will not return in time to the growth trajectory on which it was set prior to March 2020.”

Hugh Risebrow, report author

The first edition of the Diagnostics UK Market Report offers a picture of a high value and growing market which makes it highly attractive to investors. While the current crisis will undoubtedly change the market’s focus for the short-term, understanding its underlying dynamics and potential makes this report vital reading for investors, advisors, suppliers, commissioners and providers to the UK diagnostics market.

What the report covers


  • Market
  • Politics and regulation
  • Payors
  • Providers
  • Key suppliers to the market
  • Investors
  • Market potential
  • Appendices
  • Glossary

Who is the report for


  • Hospital & Clinic C-Suite Professionals
  • Specialist Diagnostics Providers
  • Suppliers of Imaging and Pathology Equipment
  • Private Medical Insurance Groups
  • Clinical Commissioning Groups
  • NHS Foundation Trusts
  • Professional and Trade Associations
  • Investors
  • Banks
  • Private Equity
  • Central and Local Government
  • Think Tanks
  • Lawyers
  • Management Consultants

Table of Contents


FOREWORDLIST OF TABLESLIST OF FIGURESEXECUTIVE SUMMARY AND HIGHLIGHTS
1. MARKET
1.1 Definitions and scope
1.1.1 Imaging
1.1.2 Pathology
1.2 Size
1.2.1 Imaging
1.3 Historic growth
1.3.1 Imaging
1.3.2 Pathology
1.3.3 Private hospitals
1.4 Segmentation/funding - by payor type
1.5 Demand drivers
1.6 Supply
1.6.1 Equipment
1.6.2 Staffing
1.7 Operating and investment models
1.7.1 Imaging
1.7.1.1 NHS contracts
1.7.1.2 Private hospital contracts
1.7.1.3 Independent imaging centres
1.7.2 Image reporting
1.7.3 Pathology
1.7.3.1 NHS joint ventures/full outsourcing
1.7.3.2 Full service private labs
1.7.3.3 Private hospital outsourcing contracts
1.7.4 Histology reporting
1.7.5 Specialist labs
2. POLITICS AND REGULATION
2.1 Current regulators and regulation
2.1.1 Care Quality Commission (CQC)
2.1.2 Health and Safety Executive (HSE)
2.1.3 Ionising Radiation Medical Exposure Regulations (IRMER)
2.1.4 The Quality Standard for Imaging (QSI)
2.1.5 ISO15189
2.1.6 Medicines and Healthcare Products Regulatory Agency (MHRA)
2.1.7 Human Tissue Authority (HTA)
3. PAYORS
3.1 Payor groups
3.1.1 NHS
3.1.2 Local authorities
3.1.3 Private hospitals and providers
3.1.4 Private Medical Insurers (PMI)
3.1.5 Self-pay but medically referred
3.1.6 Direct to consumer
3.2 Payor breakdown and analysis
3.2.1 NHS
3.2.1.1 Imaging
3.2.1.2 Private Medical Insurers (PMI) and self-pay
3.2.1.3 Pathology
3.2.2 Local authorities
3.2.3 Private providers
3.2.3.1 Imaging
3.2.3.2 Pathology
3.2.4 Private Medical Insurers (PMI)
3.2.5 Self-pay but medically referred
3.2.6 Direct to consumer
4. MAJOR PROVIDERS
4.1 Market concentration by segment
4.1.1 Image generation
4.1.2 Image reporting
4.1.3 Pathology laboratory services
4.1.4 Pathology reporting
4.2 Economies of scale and scope
4.2.1 Imaging
4.2.2 Imaging reporting
4.2.3 Pathology
4.2.4 Pathology reporting
4.3 Major provider profiles
4.3.1 Image generation service providers
4.3.1.1 Alliance Medical
4.3.1.2 InHealth
4.3.1.3 Medical Imaging Partnership
4.3.1.4 Diagnostic Healthcare
4.3.1.5 Mediscan
4.3.2 Image reporting agencies
4.3.2.1 Unilabs
4.3.2.2 Medica Group
4.3.2.3 Everlight
4.3.2.4 4ways
4.3.3 Laboratory service providers
4.3.3.1 Sonic Healthcare
4.3.3.2 SYNLAB
4.3.3.3 Eurofins Biomnis
4.3.3.4 Viapath
4.3.3.5 Source BioScience
4.3.4 Major international diagnostic service companies not currently present in the UK
4.3.4.1 LabCorp
4.3.4.2 Quest Diagnostics
4.3.4.3 amedes
4.3.4.4 Limbach Group
4.3.4.5 Medicover
4.3.4.6 Affidea
5. KEY SUPPLIERS TO THE MARKET
5.1 Major imaging suppliers
5.1.1 Philips
5.1.2 GE
5.1.3 Siemens
5.1.4 Hitachi
5.1.5 Canon
5.1.6 United Imaging
5.2 Pathology
5.2.1 Major full laboratory/managed equipment service providers
5.2.1.1 Roche
5.2.1.2 Abbott
5.2.1.3 Beckman Coulter
5.2.2 Other significant laboratory suppliers
5.2.2.1 Becton Dickinson (sample collection systems, cytology systems, microbiology automation)
5.2.2.2 Agilent (niche products including mass spectrometry)
5.2.2.3 Sysmex (haematology products)
5.2.2.4 bioMiomerieux (Microbiology products)
5.2.2.5 Thermo Fisher Scientific (a range of niche products through various subsidiaries)
5.2.2.6 Orthoclinical Diagnostics (Blood typing and ‘dry’ chemistry)
5.2.2.7 Illumina (Genetic sequencing)
5.2.2.8 Roper Technologies
6. INVESTORS
6.1 The investment case
6.2 Private Equity Investors involved in the sector and their portfolio companies
6.2.1 Selected private equity funds with assets active in the UK
6.2.1.1 Apax Partners
6.2.1.2 Apposite Capital
6.2.1.3 Cinven
6.2.1.4 Synova
6.2.1.5 Everlight
6.3 Public listed companies active in the UK
6.3.1 Life Healthcare
6.3.2 Sonic Healthcare
6.3.3 Eurofins
6.4 Major international diagnostic service groups not currently involved in the UK diagnostic market
6.4.1 Selected international diagnostic service groups not currently involved in the UK diagnostic market
6.4.1.1 Affidea
6.4.1.2 amedes
6.4.1.3 Quest Diagnostics
6.4.1.4 LabCorp
6.4.1.5 Medicover
6.5 Exits, entries, acquisitions and other key events
7. MARKET POTENTIAL
7.1 Future need, prospects
7.2 New technology
7.2.1 Genomic testing
7.2.1.1 Illumina
7.2.1.2 Grail
7.2.1.3 Helix
7.2.1.4 Foundation Medicine
7.2.1.5 Guardant
7.2.1.6 Centogene (Germany)
7.2.1.7 Gene DX
7.2.1.8 Genomic Health
7.2.1.9 Myriad Genetics
7.2.1.10 P4 Diagnostix
7.2.1.11 Natera
7.2.1.12 BGI (China)
7.2.1.13 Exact Sciences
7.2.1.14 Agendia
7.2.1.1 Biotheranostics
7.2.1.16 GenomeDX
7.2.1.17 Exosome Diagnostics
7.2.1.18 MDx Healthcare
7.2.1.19 Inivata
7.2.1.20 Oxford Cancer Biomarkers
7.2.1.21 Personal Genome Diagnostics
7.2.1.22 Nanostring Technologies
7.2.1.23 Omniseq
7.2.1.24 MML (HMDS lab in Munich)
7.2.1.25 Nimgenetics Spain
7.2.1.26 Oncologica UK
7.2.1.27 Eurofins
7.2.1.28 Synlab
7.2.1.29 Sonic (TDL parent)
7.2.1.30 Source Bioscience
7.2.1.31 LabCorp (US)
7.2.1.32 Quest Diagnostics
7.2.2 Digital histology
7.2.3 Artificial Intelligence (AI)
7.2.3.1 Kheiron Medical
7.2.3.2 Behold AI
7.2.3.3 Aidance
7.2.3.4 Zebra Med
7.2.3.5 Qure
7.2.3.6 Google
7.2.3.7 Ibex
7.3 International comparisons
7.4 Market volume, pricing and value forecasts
7.4.1 Private hospital image generation
7.4.2 NHS image reporting
7.4.3 Private image reporting
7.4.4 NHS pathology
7.4.5 Private hospital pathology
7.4.6 The ‘Retail’ imaging market
7.4.7 The ‘Retail’ pathology market
7.4.8 The overall summary of the Wholesale and Retail market values
APPENDIX 1. GLOSSARYAPPENDIX 2. REGULATORSAPPENDIX 3. TRADE BODIES AND ASSOCIATIONS

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 4ways
  • Affidea
  • Alliance Medical
  • Diagnostic Healthcare
  • Eurofins Biomnis
  • Everlight
  • InHealth
  • LabCorp
  • Limbach Group
  • Medica Group
  • Medical Imaging Partnership
  • Medicover
  • Mediscan
  • Quest Diagnostics
  • SYNLAB
  • Sonic Healthcare
  • Source BioScience
  • Unilabs
  • Viapath
  • amedes